Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

Michael A. Badruddoja; Marjorie Pazzi; Abhay Sanan; Kurt Schroeder; Kevin Kuzma; Thomas Norton; Thomas Scully; Daruka Mahadevan; Michael Malek Ahmadi

doi:10.1007/s00280-017-3448-9

Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

Michael A. Badruddoja, Marjorie Pazzi, Abhay Sanan, Kurt Schroeder, Kevin Kuzma, Thomas Norton, Thomas Scully, Daruka Mahadevan, Michael Malek Ahmadi

Resultado de la investigación: Comment/debate › revisión exhaustiva

1 Cita (Scopus)

Resumen

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

Idioma original	English (US)
Páginas (desde-hasta)	223
Número de páginas	1
Publicación	Cancer chemotherapy and pharmacology
Volumen	81
N.º	1
DOI	https://doi.org/10.1007/s00280-017-3448-9
Estado	Published - ene 1 2018
Publicado de forma externa	Sí

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Acceder al documento

10.1007/s00280-017-3448-9

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)'. En conjunto forman una huella única.

Citar esto

Badruddoja, M. A., Pazzi, M., Sanan, A., Schroeder, K., Kuzma, K., Norton, T., Scully, T., Mahadevan, D., & Ahmadi, M. M. (2018). Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7). Cancer chemotherapy and pharmacology, 81(1), 223. https://doi.org/10.1007/s00280-017-3448-9

Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7). / Badruddoja, Michael A.; Pazzi, Marjorie; Sanan, Abhay et al.
En: Cancer chemotherapy and pharmacology, Vol. 81, N.º 1, 01.01.2018, p. 223.

Resultado de la investigación: Comment/debate › revisión exhaustiva

Badruddoja, MA, Pazzi, M, Sanan, A, Schroeder, K, Kuzma, K, Norton, T, Scully, T, Mahadevan, D & Ahmadi, MM 2018, 'Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)', Cancer chemotherapy and pharmacology, vol. 81, n.º 1, pp. 223. https://doi.org/10.1007/s00280-017-3448-9

Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T et al. Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7). Cancer chemotherapy and pharmacology. 2018 ene 1;81(1):223. doi: 10.1007/s00280-017-3448-9

@article{e4281c3194394543a1ef9e30e6938739,

title = "Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)",

abstract = "The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].",

author = "Badruddoja, {Michael A.} and Marjorie Pazzi and Abhay Sanan and Kurt Schroeder and Kevin Kuzma and Thomas Norton and Thomas Scully and Daruka Mahadevan and Ahmadi, {Michael Malek}",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/s00280-017-3448-9",

language = "English (US)",

volume = "81",

pages = "223",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

AU - Badruddoja, Michael A.

AU - Pazzi, Marjorie

AU - Sanan, Abhay

AU - Schroeder, Kurt

AU - Kuzma, Kevin

AU - Norton, Thomas

AU - Scully, Thomas

AU - Mahadevan, Daruka

AU - Ahmadi, Michael Malek

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

AB - The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

UR - http://www.scopus.com/inward/record.url?scp=85031502938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031502938&partnerID=8YFLogxK

U2 - 10.1007/s00280-017-3448-9

DO - 10.1007/s00280-017-3448-9

M3 - Comment/debate

C2 - 29034406

AN - SCOPUS:85031502938

SN - 0344-5704

VL - 81

SP - 223

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -